Jubbonti ® (denosumab-bbdz) and Wyost ® (denosumab-bbdz), interchangeable biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively, are now available from Sandoz. The ...

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

Patients with prostate cancer may have a lower risk of recurrence if they take multivitamin supplements after diagnosis, new data suggest.

The study will assess the number and severity of dose-limiting toxicities and adverse events. A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells ...

Health care data breaches that compromised protected health information more than doubled from 2010 to 2024 in the US, data suggest.

Engaging in leisure-time MVPA linked to improved survival for various cancer types including bladder, breast, colon. (HealthDay News) — Engaging in leisure-time moderate- to vigorous-intensity ...

One-year incidence of psychosocial therapy initiation was 12.6 percent, while incidence of medication initiation was 2.8 percent ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Adding zilebesiran to a thiazide diuretic or calcium channel blocker may lead to further blood pressure reduction in patients with uncontrolled hypertension. Zilebesiran added to hypertension ...

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...